[Histonet] Validating IHC on decalcified specimens

[Cartun, Richard]

I have a validation file for ER, PR, and HER2 IHC testing on decalcified bone specimens with metastatic breast cancer.  I compared the results with other specimens from the same patient (usually the primary breast cancer) that were not decalcified.

Richard

Richard W. Cartun, MS, PhD
Director, Histology & The Martin M. Berman, MD Immunopathology & Morphologic Proteomics Laboratory
Director, Biospecimen Collection Programs
Assistant Director, Anatomic Pathology
Hartford Hospital
80 Seymour Street
Hartford, CT  06102
(860) 972-1596
(860) 545-2204 Fax

-----Original Message-----
From: Teri Johnson via Histonet [mailto:histonet at lists.utsouthwestern.edu]
Sent: Tuesday, April 05, 2016 2:50 PM
To: 'histonet at lists.utsouthwestern.edu'
Subject: [Histonet] Validating IHC on decalcified specimens

Hi Histonetters,

Can someone tell me if they do anything specific to validate their IHC markers on decalcified specimens? If no, do you test them anyway?

Teri Johnson
Manager, Clinical Trial Testing
Genoptix, Inc., a Novartis company
BioPharma
1811 Aston Avenue
Carlsbad, CA  92008
USA

Phone +1 760 516 5954
tejohnson at genoptix.com<mailto:tejohnson at genoptix.com>
www.genoptix.com<http://www.genoptix.com/>


________________________________

CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and contains information that is confidential and proprietary to Genoptix Medical Laboratory or its subsidiaries. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, immediately contact the sender by e-mail and destroy all copies of the original message.
_______________________________________________
Histonet mailing list
Histonet at lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet

This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, or distribution is prohibited. If you are not the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message, including any attachments.